Logo

EVGN

Evogene Ltd.

EVGN

Evogene Ltd. • NASDAQ
$1.06 ▼ -6.61% (-0.07)
Market Cap $9.24 M
52w High $2.42
52w Low $0.95
Dividend Yield 0%
P/E -0.96
Volume 30.62K
Outstanding Shares 8.72M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $312K ▼ $2.589M ▼ $3.874M ▲ 1.242K% ▲ $0.44 ▲ $-1.978M ▲
Q2-2025 $884K ▼ $3.529M ▼ $-4.462M ▼ -504.751% ▼ $-0.62 ▼ $-2.546M ▼
Q1-2025 $2.444M ▲ $4.568M ▼ $-2.587M ▼ -105.851% ▼ $-0.38 ▼ $-1.944M ▼
Q4-2024 $1.611M ▼ $4.83M ▼ $427K ▲ 26.505% ▲ $0.063 ▲ $752K ▲
Q3-2024 $1.74M $6.409M $-7.63M -438.506% $-1.31 $-3.643M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $15.958M ▲ $26.086M ▼ $5.997M ▼ $1.142M ▲
Q2-2025 $11.691M ▲ $33.926M ▼ $21.551M ▼ $-3.55M ▲
Q1-2025 $9.849M ▼ $34.304M ▼ $21.909M ▼ $-3.645M ▼
Q4-2024 $15.311M ▼ $39.864M ▼ $25.026M ▼ $-1.451M ▲
Q3-2024 $19.953M $40.114M $27.876M $-4.343M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.052M ▼ $-3.791M ▲ $11.267M ▲ $-10.645M ▼ $-2.703M ▼ $-3.802M ▼
Q2-2025 $-3.529M ▼ $-7.519M ▼ $-989K ▲ $4.149M ▲ $834K ▲ $-2.303M ▲
Q1-2025 $-2.989M ▼ $-5.182M ▲ $-2.446M ▼ $-159K ▼ $-7.806M ▼ $-5.304M ▲
Q4-2024 $-5K ▲ $-5.207M ▼ $8.758M ▲ $440K ▼ $3.984M ▲ $-5.529M ▼
Q3-2024 $-8.219M $-4.928M $2.016M $4.734M $1.833M $-5.06M

Five-Year Company Overview

Income Statement

Income Statement Evogene’s income statement looks like that of an early-stage R&D platform company rather than a commercial operator. Revenue is essentially negligible, so the business is still living off future potential rather than current sales. Operating and net results have been consistently negative, with losses fairly steady over the last few years rather than exploding, which suggests cost discipline but no clear path to break-even yet. Earnings per share appear volatile partly because of reverse stock splits, not because of a sudden change in the underlying business. Overall, financial performance still depends almost entirely on turning its technology and subsidiaries into paying partnerships, licensing deals, or product revenues over time.

Balance Sheet

Balance Sheet The balance sheet is small and quite lean, with cash making up a large share of total assets. Cash levels have edged down over time, and shareholders’ equity has been eroded, leaving only a thin capital cushion. The company carries only modest debt, which reduces interest pressure but also reflects limited traditional borrowing capacity. In practical terms, Evogene’s financial flexibility looks constrained and sensitive to any setbacks, so it likely depends on external funding, partnerships, or asset sales to support operations. The small scale means even moderate changes in funding or results can have an outsized impact.

Cash Flow

Cash Flow Cash flow highlights a steady, ongoing cash burn from operations, typical of a company heavily focused on research rather than sales. Operating cash outflows have been fairly stable year after year, indicating controlled but persistent spending without self-funding growth. Capital expenditures are minimal, so most cash use is for people, trials, and development rather than buildings or equipment. Free cash flow is therefore consistently negative, and sustainability depends on access to cash from investors, partners, or transactions like the Lavie Bio asset sale. Any delay in deals or milestones could quickly pressure liquidity given the modest cash base.

Competitive Edge

Competitive Edge Evogene’s competitive position is built around its proprietary AI-driven biology platforms, which are not trivial to replicate. The combination of large, curated datasets, specialized algorithms, and cross-disciplinary expertise creates a meaningful barrier for new entrants. Its subsidiary structure lets each business focus on a specific niche—drugs, crop protection, medical cannabis, and industrial seeds—while all draw on the same core technology. At the same time, Evogene competes in industries dominated by much larger pharmaceutical and agricultural companies, so its leverage often depends on proving that its platforms materially improve R&D outcomes. Until there is broader commercial validation and recurring revenue, its bargaining power remains more promise-based than fully established.

Innovation and R&D

Innovation and R&D Innovation is clearly the heart of Evogene’s story. The three main AI engines—ChemPass, MicroBoost, and GeneRator—are designed to accelerate discovery in small molecules, microbes, and genetics, respectively, and are already feeding multiple pipelines. Subsidiaries like Biomica, AgPlenus, Canonic, and Casterra showcase how the same computational core can be applied to cancer therapies, herbicides, tailored cannabis, and biofuel crops. The recent sale of most of Lavie Bio’s activities suggests a shift toward sharpening focus, especially on pharmaceutical opportunities through ChemPass, while using non-dilutive capital to keep R&D moving. However, much of the pipeline is still in early or mid stages, so scientific risk, regulatory risk, and timing uncertainty remain high.

Summary

Evogene today is primarily a technology and R&D platform company with very little revenue, recurring losses, and a relatively thin balance-sheet buffer. Its financial profile reflects a long-term, high-risk development phase rather than a mature operating business. On the positive side, it has built a differentiated suite of AI biology tools and a portfolio of focused subsidiaries that give it multiple shots on goal across healthcare, agriculture, and industrial applications. The sale of Lavie Bio’s assets strengthens liquidity and allows greater strategic focus, but does not remove the fundamental dependence on future deals, clinical progress, and product adoption. Overall, the story is one of strong innovation potential balanced against significant execution and financing risk, with outcomes likely to unfold over many years rather than quarters.

NEWS

November 20, 2025 · 7:51 PM UTC

EverGen Infrastructure Reports Q3 2025 Results

Read more

November 20, 2025 · 7:00 AM UTC

Evogene Reports Third Quarter 2025 Financial Results

Read more

November 11, 2025 · 7:00 AM UTC

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Read more

November 6, 2025 · 9:00 AM UTC

Evogene Schedules Third Quarter 2025 Financial Results Release

Read more

September 26, 2025 · 7:13 PM UTC

EverGen Infrastructure Provides Operations and Development Updates

Read more